Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review.

Cytogenetic abnormalities are found in 50-60% of newly diagnosed acute myeloid leukemia (AML) of adult patients. Cytogenetic analysis of bone marrow leukemic cells is an important pre-treatment evaluation for a correct prognostic stratification of patients, that permit to separate AML patients in three broad prognostic categories: high, intermediate and low risk. The determination of cytogenetic features of AML remains a corner stone in predicting outcome although today its use needs to be integrated by molecular and immunophenotypic data, particularly in cytogenetically normal (CN) group of patients. In this review we perform a concise description of more recurrent cytogenetic aberrations found in AML, theirs correlations with biological and clinical data and theirs strong impact with outcome of patients, useful for therapeutic decision.

[1]  D. Birnbaum,et al.  MOZ is fused to p300 in an acute monocytic leukemia with t(8;22) , 2000, Genes, chromosomes & cancer.

[2]  J. Ihle,et al.  DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. , 1994, Blood.

[3]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[4]  T. Taki,et al.  Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia , 2001, Genes, chromosomes & cancer.

[5]  P. Aplan,et al.  The role of CALM–AF10 gene fusion in acute leukemia , 2008, Leukemia.

[6]  B. Johansson,et al.  Acute Myeloid Leukemia with inv(8)(p11q13) , 2000, Leukemia & lymphoma.

[7]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[8]  C. Bloomfield,et al.  Clinical significance of cytogenetics in acute myeloid leukemia. , 1997, Seminars in oncology.

[9]  S. Izraeli,et al.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. , 2009, Blood.

[10]  C. Bloomfield,et al.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Giphart-Gassler,et al.  Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. , 2007, Haematologica.

[12]  H. Döhner.  Implication of the molecular characterization of acute myeloid leukemia. , 2007, Hematology. American Society of Hematology. Education Program.

[13]  A. Zanella,et al.  HIC gene, a candidate suppressor gene within a minimal region of loss at 7q31.1 in myeloid neoplasms. , 2007, Leukemia research.

[14]  A. Wozniak,et al.  Cytogenetic analysis and clinical significance of chromosome 7 aberrations in acute leukaemia. , 2003, Journal of applied genetics.

[15]  R. Berger,et al.  Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ? , 2007, Cancer genetics and cytogenetics.

[16]  J. Goldman,et al.  Two cases of inv(8)(p11q13) in AML with erythrophagocytosis: a new cytogenetic variant , 1998, British journal of haematology.

[17]  T. Rabbitts,et al.  Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. , 2004, Genes & development.

[18]  T. Leblanc,et al.  DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification , 2005, Leukemia.

[19]  M. Caligiuri,et al.  Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications , 1999, Annals of Hematology.

[20]  K. Oshimi,et al.  Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study , 2008, International journal of hematology.

[21]  C. Bloomfield,et al.  Cytogenetics in acute leukemia. , 2004, Blood reviews.

[22]  A. Hirt,et al.  The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG) , 2007, European journal of haematology.

[23]  R. Aguiar,et al.  A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. , 1998, Blood.

[24]  Paola Fazi,et al.  Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia , 2008, Haematologica.

[25]  L. Medeiros,et al.  Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. , 2004, American journal of clinical pathology.

[26]  W. Hiddemann,et al.  Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients , 2001, British journal of haematology.

[27]  M. Gordon.  Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study , 2008 .

[28]  D. Birnbaum,et al.  Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique , 2008, Leukemia.

[29]  C. Disteche,et al.  The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein , 1996, Nature Genetics.

[30]  Stefan Fröhling,et al.  Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Torsten Haferlach,et al.  Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile , 2005, Genes, chromosomes & cancer.

[32]  C. Bloomfield,et al.  Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Birnbaum,et al.  NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia , 2008, Leukemia.

[34]  M. Vignetti,et al.  Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation , 2009, Haematologica.

[35]  W. Blum.  Post-remission therapy in acute myeloid leukemia: what should I do now? , 2008, Haematologica.

[36]  C. Bloomfield,et al.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.

[37]  M. Odero,et al.  Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements , 2004, Genes, chromosomes & cancer.

[38]  F. Behm,et al.  Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints , 1998, Leukemia.

[39]  F. Speleman,et al.  Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using m‐FISH , 2002, Genes, chromosomes & cancer.

[40]  J. Rowley,et al.  Chromatin structural elements and chromosomal translocations in leukemia. , 2006, DNA repair.

[41]  C. Bloomfield,et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.

[42]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  B. Johansson,et al.  The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. , 2001, Cancer genetics and cytogenetics.

[44]  I. Bar-Am,et al.  Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel , 2004, British journal of haematology.

[45]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[46]  K. Döhner,et al.  Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  C. Bloomfield,et al.  Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. , 2006, Hematology. American Society of Hematology. Education Program.

[48]  K. Döhner,et al.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Schlenk,et al.  Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. , 2007, Haematologica.

[50]  C. Mecucci,et al.  Translocation t(8;16)(p11;p13) in acute non-lymphocytic leukemia: report on two new cases and review of the literature. , 1996, Leukemia & lymphoma.

[51]  M. Slovak,et al.  Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. , 2003, Human pathology.

[52]  R. Drouin,et al.  Tetrasomy 8 is associated with a major cellular proliferative advantage and a poor prognosis. two cases of myeloid hematologic disorders and review of the literature. , 2001, Cancer genetics and cytogenetics.

[53]  S. Fröhling,et al.  Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.

[54]  S. Fröhling,et al.  Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.

[55]  A. Hagemeijer,et al.  Trisomy 11 in myeloid malignancies is associated with internal tandem duplication of both MLL and FLT3 genes. , 2005, Haematologica.

[56]  J. Welborn.  Constitutional chromosome aberrations as pathogenetic events in hematologic malignancies. , 2004, Cancer genetics and cytogenetics.

[57]  R. Hills,et al.  Treatment for myeloid leukaemia of Down syndrome: population‐based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials , 2006, British journal of haematology.

[58]  C. Bloomfield,et al.  Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  C. Bloomfield,et al.  11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop † , 2002, Genes, chromosomes & cancer.

[60]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[61]  G. Martinelli,et al.  3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. , 1999, Haematologica.

[62]  K. Mrózek,et al.  Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. , 2008, Seminars in oncology.

[63]  F. Lo‐Coco,et al.  Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of MLL Gene Translocation Results in 378 Adult Patients , 2004 .

[64]  A. Borkhardt,et al.  Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: Almost identical MLL breakpoints in therapy‐related AML after treatment without etoposides , 2003, Genes, chromosomes & cancer.

[65]  L. Shaffer,et al.  Deletions of chromosome arms 7p and 7q in adult acute myeloid leukemia: a marker chromosome confirmed by array comparative genomic hybridization. , 2009, Cancer genetics and cytogenetics.

[66]  N. Gutiérrez,et al.  Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11. , 2005, Cancer genetics and cytogenetics.

[67]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[68]  M. Slovak,et al.  Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. , 1997, American journal of clinical pathology.

[69]  Yi Ning,et al.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.

[70]  J. Wolstenholme.  CONFINED PLACENTAL MOSAICISM FOR TRISOMIES 2, 3, 7, 8, 9, 16, AND 22: THEIR INCIDENCE, LIKELY ORIGINS, AND MECHANISMS FOR CELL LINEAGE COMPARTMENTALIZATION , 1996, Prenatal diagnosis.

[71]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[72]  M. Varella‐Garcia,et al.  Translocation (11;19)(q23;p13.3) associated with a novel t(5;16) (q13;q22) in a patient with acute myelocytic leukemia. , 2003, Cancer genetics and cytogenetics.

[73]  J. Downing.  The core-binding factor leukemias: lessons learned from murine models. , 2003, Current opinion in genetics & development.

[74]  T. de Souza Fernandez,et al.  c-MYC amplification in a case of progression from MDS to AML (M2) , 1996, Cancer genetics and cytogenetics.

[75]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  N. Speck.  Core binding factor and its role in normal hematopoietic development. , 2001, Current opinion in hematology.

[77]  C. Bloomfield,et al.  Clinical importance of cytogenetics in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[78]  M. Cleary,et al.  Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins , 2001, Oncogene.

[79]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[80]  J. Harbott,et al.  Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7 , 1999, Leukemia.

[81]  B. Bain,et al.  Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study , 1995, British journal of haematology.

[82]  B. Johansson,et al.  Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. , 2007, Pathologie-biologie.

[83]  C. Bloomfield,et al.  Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study , 1998, British journal of haematology.

[84]  Roberta Riccioni,et al.  Deregulation of apoptosis in acute myeloid leukemia. , 2007, Haematologica.

[85]  F. Lo Coco,et al.  Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  H. Dombret,et al.  Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.

[87]  M. Grever,et al.  Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Mehta,et al.  Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. , 2007, Blood.

[90]  H. Dombret,et al.  Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial , 2000, British journal of haematology.

[91]  V. Lindgren,et al.  Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. , 2008, Archives of pathology & laboratory medicine.

[92]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[93]  T. Kyo,et al.  Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. , 1992, Blood.

[94]  T. Haferlach,et al.  Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. , 2007, Blood.

[95]  C. Bloomfield,et al.  Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review , 2007, British journal of haematology.

[96]  C. Bloomfield,et al.  A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies , 2006, Leukemia.

[97]  T. Sun,et al.  Acute monoblastic leukemia with t(8;16): A distinct clinicopathologic entity; Report of a case and review of the literature , 2001, American journal of hematology.

[98]  J. Byrd,et al.  Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. , 2009, Blood.

[99]  S. Morris,et al.  MNDA binds NPM/B23 and the NPM-MLF1 chimera generated by the t(3;5) associated with myelodysplastic syndrome and acute myeloid leukemia. , 1997, Experimental hematology.